SIGNIFICANT EVENTS |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| SIGNIFICANT EVENTS | |
| SIGNIFICANT EVENTS | NOTE 17 – SIGNIFICANT EVENTS
In July 2025, the Company, through MRNA Scientific Sdn. Bhd., entered into a nonbinding term sheet with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) concerning a proposed strategic cross-equity alliance and exclusive commercialization rights for the VitaGuard™ minimal residual disease (“MRD”) platform in Southeast Asia. On November 28, 2025, the Company completed the Share Subscription and Shareholders’ Agreement with Fidelion and the other parties thereto and entered into an Intellectual Property License Agreement under which the Company obtained exclusive, perpetual commercialization rights for VitaGuard in the ASEAN region. VitaGuard is being developed for liquid-biopsy MRD monitoring. As of September 30, 2026, the platform remained in the commercialization and implementation stage in ASEAN and had not begun generating revenue for the Company.
On November 20, 2025, the Company’s Board of Directors adopted the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan (the “Incentive Plan”), which was approved by the Company’s shareholders at the annual meeting held on December 24, 2025. The Incentive Plan initially reserved 472,767 shares of common stock for issuance and provides for annual increases in the share reserve in accordance with its terms. The Incentive Plan reserve for 2026 is 593,632 shares.
On May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. Based on its ongoing investigation, the Company alleges that the former officers and directors caused these amounts to be paid from Chemrex’s corporate accounts during the period from July 2024 through August 2025. The Company alleges that the transactions were unauthorized under Malaysian law; these allegations have not been adjudicated by a court or tribunal. The Company continues to investigate the activities of these parties and their effect on Chemrex. The Company intends to pursue available claims and remedies, as appropriate. As of the date of this report, no court or tribunal proceeding has been commenced in connection with the Letters of Demand.
On August 13, 2026, the Company issued an aggregate of 516,128 shares of its common stock, no par value per share, under the Company’s shareholder-approved 2025 Equity Incentive Plan. Each award was a fully vested Other Stock-Based Award under Section 5 of the plan, issued on a bonus basis as compensation for completed services and for no cash consideration. The awards were measured at a grant-date fair value of $1.55 per share, based on the Nasdaq closing price on August 12, 2026, the last closing price before the awards were granted, for an aggregate of $799,998, which was recognized as share-based compensation expense in the three-month period ended September 30, 2026. The awards consisted of 338,709 shares to Su-Leng Tan Lee, the Company’s Chief Executive Officer and President; 96,774 shares to Set Fui Chong, the Company’s Chief Financial Officer and Principal Financial Officer; 32,258 shares to Muhammad Azrul bin Abdul Hamid, an independent director; 32,258 shares to Chee Keong Yap, an independent director; and 16,129 shares to Jook Yuen Low, an independent director. Following the issuances, 77,504 shares remained available under the plan and the Company had 2,933,442 shares of common stock issued and outstanding. The Company relied on Regulation S under the Securities Act of 1933 for the offshore issuances. The shares are restricted securities and remain subject to applicable transfer restrictions.
Also on August 13, 2026, the Board reappointed Su-Leng Tan Lee as Chief Executive Officer and President for a fixed term commencing September 1, 2026 and ending August 31, 2029 and approved a new employment agreement effective September 1, 2026. The agreement provides for gross base salary of $35,000 per month, an annual discretionary cash-bonus review with no guaranteed minimum or target, and termination by either party on six months’ written notice, subject to its other terms. |